著者
Yumi KONDO Kazuaki TAKASHIMA Satoshi MATSUMOTO Masahiro SHIBA Tomoko OTSUKI Gen KINOSHITA Joseph ROSENTEL Sheila J. GROSS Candis FLEISHMAN Yoshihisa YAMANE
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
vol.74, no.10, pp.1283-1289, 2012 (Released:2012-11-02)
参考文献数
18
被引用文献数
3 11 1

Use of firocoxib in dogs for postoperative pain control has not been published in any of the journals in Japan. A field study was conducted to evaluate the efficacy and safety of firocoxib in dogs in controlling pain associated with soft tissue surgery in Japan. The study followed a negative control, double-blind, multicenter clinical efficacy study using a randomized block design. A total of 131 client-owned dogs presented to the clinical practices for soft tissue surgery were enrolled. Sixty-nine dogs were allocated to the firocoxib-treated group and received 5 mg/kg of firocoxib orally on Day 0 before the surgery and once daily through Day 2, while 62 dogs were allocated to the non-treated group handled in a similar manner only without the firocoxib administration. Pain assessment took place on Day 0 before the surgery through Day 2. The primary efficacy variable was a success/failure variable based on whether the dog needed rescue medication (based on pain assessment after the surgery or Investigator’s judgment) and a significant difference between firocoxib-treated group (16.4%) and non-treated group (50.0%) (P=0.0031) was observed. There was no adverse event during the study that was considered to be related to the administration of firocoxib. This study indicated the clinical efficacy and safety profile of firocoxib administered to control pain associated with soft tissue surgery under field condition.
著者
Hiroshi UENO Kenjiro MIYOSHI Sho FUKUI Yumi KONDO Kazuya MATSUDA Tsuyoshi UCHIDE
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.13-0159, (Released:2014-01-13)
被引用文献数
2 14

An 8-year-old neutered female Cavalier King Charles Spaniel was evaluated for progressing right forelimb lameness. Upon magnetic resonance imaging, the right-sided radius nerves and the caudal brachial plexus were swelled. The histological and molecular biological diagnosis of partial the C8 spinal nerve was T-cell lymphoma. Co-administration of lomustine and irradiation was started. However, this therapy was ineffective. At necropsy, neoplastic tissues were seen extending into the subarachnoid space of the spinal cord, the liver, pancreas and kidneys as gross findings. A large mass was also identified occupying the caudal thorax. Histologic findings included infiltration in these organs and mass by neoplastic lymphocytes. To date, involvement of peripheral nerves (neurolymphomatosis) is rarely reported in veterinary species.
著者
Yumi KONDO Kazuaki TAKASHIMA Satoshi MATSUMOTO Masahiro SHIBA Tomoko OTSUKI Gen KINOSHITA Joseph ROSENTEL Sheila J. GROSS Candis FLEISHMAN Yoshihisa YAMANE
出版者
公益社団法人 日本獣医学会
雑誌
Journal of Veterinary Medical Science (ISSN:09167250)
巻号頁・発行日
pp.11-0306, (Released:2012-05-31)
被引用文献数
3 11

Use of firocoxib in dogs for postoperative pain control has not been published in any of the journals in Japan. A field study was conducted to evaluate the efficacy and safety of firocoxib in dogs in controlling pain associated with soft tissue surgery in Japan. The study followed a negative control, double-blind, multicenter clinical efficacy study using a randomized block design. A total of 131 client-owned dogs presented to the clinical practices for soft tissue surgery were enrolled. Sixty-nine dogs were allocated to the firocoxib-treated group and received 5 mg/kg of firocoxib orally on Day 0 before the surgery and once daily through Day 2, while 62 dogs were allocated to the non-treated group handled in a similar manner only without the firocoxib administration. Pain assessment took place on Day 0 before the surgery through Day 2. The primary efficacy variable was a success/failure variable based on whether the dog needed rescue medication (based on pain assessment after the surgery or Investigator’s judgment) and a significant difference between firocoxib-treated group (16.4%) and non-treated group (50.0%) (P=0.0031) was observed. There was no adverse event during the study that was considered to be related to the administration of firocoxib. This study indicated the clinical efficacy and safety profile of firocoxib administered to control pain associated with soft tissue surgery under field condition.